세계의 마취제 시장 : 약제 클래스별, 투여 경로별, 용도별, 최종사용자별, 지역별, 기회 및 예측(2018-2032년)

Global anesthesia drugs market is projected to witness a CAGR of 4.73% during the forecast period 2025-2032, growing from USD 7.71 billion in 2024 to USD 11.16 billion in 2032. The market's growth can be attributed to the rising cases of chronic diseases, increasing reliance on surgical procedures, and the expansion of the aging population. The World Health Organization (WHO) estimates that cardiovascular diseases are the leading cause of death and claim approximately 17.9 million lives every year.

From elective cosmetic surgeries to complex organ transplants, almost all procedures call for anesthesia to maintain patient safety and comfort during the procedure. With the ever-rising cases of chronic and lifestyle diseases, the number of surgeries is expected to increase significantly in the coming years. The elderly population around the world further supports this trend; elderly patients often require surgical care for degenerative conditions such as osteoarthritis, cataracts, and cardiovascular disorders, among others.

Hospitals and outpatient surgery centers are witnessing a rise in both inpatient and daycare surgeries, thereby sustaining the demand for general, regional, and local anesthetics. Technological advancements, including integrated anesthesia delivery systems and real-time patient monitoring, are improving the precision and safety of anesthesia drug delivery during procedures.

Increasing Prevalence of Chronic Diseases Boosts Market Demand

The rising numbers of chronic diseases are significantly driving the growth of the anesthesia drugs market. Chronic conditions such as cardiovascular diseases, diabetes, cancer, and obesity often require surgical intervention for treatment or disease management. As per the estimates of the World Obesity Federation, more than one billion people across the globe were living with obesity in 2024. With the rising burden of such diseases, there is an increase in demand for anesthesia drugs. Among the several interventions required for cardiovascular diseases, bypass surgeries and angioplasties depend on anesthesia for patient safety and comfort. Similarly, various orthopedic procedures also rely on anesthesia drugs in cases where surgeries are essential.

Meanwhile, advancements in medical technology have increased the safety and accessibility of surgeries to patients who might otherwise not undergo the procedure. This has led to an increase in demand for general and local anesthetics, depending on the requirements of the procedure and the patient population.

Novel Launches by Key Players Support Market Expansion

The recent introduction of new anesthesia drugs and formulations is facilitating the safety, efficacy, and convenience in the administration of anesthesia. For instance, in February 2024, Hikama Pharmaceuticals plc introduced Fentanyl Citrate Injection, USP, in prefilled syringes in the United States. The product is designed for short-duration analgesic use during anesthetic periods, including pre-medication, induction, maintenance, and postoperative recovery. It can also serve as a narcotic analgesic supplement in general or regional anesthesia and as an anesthetic agent with oxygen for high-risk patients undergoing complex procedures such as open-heart surgeries. With this launch, the company aims to enhance patient care by providing new dosage forms and expanding the choice of essential medicines available to hospitals and patients.

These launches are supported by ongoing research and development activities that focus on creating ultra-short-acting anesthetics and advanced delivery systems. The introduction of innovative products aids in improving patient outcomes while expanding the scope of surgical procedures that can be performed under general anesthesia.

Knee and Hip Replacements Dominate the Market

The segment's growth is supported by the increasing prevalence of osteoarthritis in various regions across the globe, rapid expansion of the aging population, and advancements in surgical techniques. The World Health Organization (WHO) estimates that one in six individuals across the globe will be sixty or older by 2030. The dominance of this segment in the market is also supported by favorable reimbursement policies and robust healthcare infrastructure in regions like North America, which holds a significant share of the global anesthesia drugs market.

Meanwhile, cancer is anticipated to witness the fastest growth in the coming years as the number of people affected by cancer increases due to increasing exposure to known risk factors. Types of cancer, such as breast cancer and lung cancer, require surgical intervention for effectively combating the condition and thus require general anesthesia.

North America Holds Major Market Share

The growth of the anesthesia drugs market in North America can be attributed to the rising prevalence of various chronic diseases and disorders, strong presence of leading pharmaceutical companies and a well-developed healthcare sector, and continuous emphasis on technological innovations. The increasing cases of conditions, including cancer and cardiovascular diseases, among others, that often require surgical intervention for appropriately treating the condition are bolstering the market's demand. The American Cancer Society estimates that approximately 2,041,910 new cancer cases will be reported in the United States in 2025. Additionally, the rising demand for minimally invasive surgeries and cosmetic procedures, which often involve anesthesia, is also contributing significantly to the market's expansion. Furthermore, advancements in anesthesia technology, such as safer anesthetic agents and administration, enhance patient safety and comfort, further boosting the market's demand. The market is also influenced by regulatory support and educational initiatives that emphasize safe anesthesia practices. For instance, organizations such as the American Association of Nurse Anesthesiologists promote awareness about the importance of safe dental anesthesia care, among others.

Future Market Scenario (2025 - 2032F)

The market is anticipated to see a gradual rise in demand due to an increasing number of surgeries, upgradation of healthcare infrastructure in different regions across the globe, and rising awareness about advanced anesthesia techniques. The transition to outpatient surgeries, along with increasing implementation of pain-free surgery, is further expected to accelerate the demand for faster and specific anesthetics. In addition, the market is also expected to benefit from AI drug delivery device development as well as innovations that focus on green anesthesia, intended to reduce the negative environmental impacts of anesthesia drugs. Furthermore, the rapid expansion of the aging population is also expected to bolster the market's demand as the older population is more susceptible to different diseases, disorders, and injuries.

Key Players Landscape and Outlook

The key players of the market are focusing on expanding their market presence in different regions across the globe by enhancing their product portfolios. For instance, in April 2024, Baxter International Inc. announced the expansion of its pharma portfolio with the launch of five injectables in the United States. The products launched by the company include norepinephrine bitartrate in 5% dextrose injection, vasopressin in 0.9% sodium chloride injection, vancomycin injection, USP, ropivacaine hydrochloride injection, USP, and regadenoson injection pre-filled syringe. The availability of these products addresses the unmet requirements of the patient population in key therapeutic areas. Thus, this expansion meets the increasing demand for safe and effective anesthesia solutions, driving the market's expansion.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Anesthesia Drugs Market Outlook, 2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Drugs Class
    • 4.2.1.1. Sevoflurane
    • 4.2.1.2. Propofol
    • 4.2.1.3. Dexmedetomidine
    • 4.2.1.4. Remifentanil
    • 4.2.1.5. Desflurane
    • 4.2.1.6. Midazolam
    • 4.2.1.7. Others
  • 4.2.2. By Route of Administration
    • 4.2.2.1. Intravenous
    • 4.2.2.2. Inhaled
  • 4.2.3. By Application
    • 4.2.3.1. Heart Surgeries
    • 4.2.3.2. Cancer
    • 4.2.3.3. General Surgery
    • 4.2.3.4. Knee and Hip Replacements
    • 4.2.3.5. Others
  • 4.2.4. By End-user
    • 4.2.4.1. Hospitals
    • 4.2.4.2. Ambulatory Surgical Centers
    • 4.2.4.3. Others
  • 4.2.5. By Region
    • 4.2.5.1. North America
    • 4.2.5.2. Europe
    • 4.2.5.3. Asia-Pacific
    • 4.2.5.4. South America
    • 4.2.5.5. Middle East and Africa
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 4.3. Market Map Analysis, 2024
  • 4.3.1. By Drugs Class
  • 4.3.2. By Route of Administration
  • 4.3.3. By Application
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. North America Anesthesia Drugs Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Drugs Class
    • 5.2.1.1. Sevoflurane
    • 5.2.1.2. Propofol
    • 5.2.1.3. Dexmedetomidine
    • 5.2.1.4. Remifentanil
    • 5.2.1.5. Desflurane
    • 5.2.1.6. Midazolam
    • 5.2.1.7. Others
  • 5.2.2. By Route of Administration
    • 5.2.2.1. Intravenous
    • 5.2.2.2. Inhaled
  • 5.2.3. By Application
    • 5.2.3.1. Heart Surgeries
    • 5.2.3.2. Cancer
    • 5.2.3.3. General Surgery
    • 5.2.3.4. Knee and Hip Replacements
    • 5.2.3.5. Others
  • 5.2.4. By End-user
    • 5.2.4.1. Hospitals
    • 5.2.4.2. Ambulatory Surgical Centers
    • 5.2.4.3. Others
  • 5.2.5. By Country Share
    • 5.2.5.1. United States
    • 5.2.5.2. Canada
    • 5.2.5.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Anesthesia Drugs Market Outlook, 2018-2032F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Drugs Class
        • 5.3.1.2.1.1. Sevoflurane
        • 5.3.1.2.1.2. Propofol
        • 5.3.1.2.1.3. Dexmedetomidine
        • 5.3.1.2.1.4. Remifentanil
        • 5.3.1.2.1.5. Desflurane
        • 5.3.1.2.1.6. Midazolam
        • 5.3.1.2.1.7. Others
      • 5.3.1.2.2. By Route of Administration
        • 5.3.1.2.2.1. Intravenous
        • 5.3.1.2.2.2. Inhaled
      • 5.3.1.2.3. By Application
        • 5.3.1.2.3.1. Heart Surgeries
        • 5.3.1.2.3.2. Cancer
        • 5.3.1.2.3.3. General Surgery
        • 5.3.1.2.3.4. Knee and Hip Replacements
        • 5.3.1.2.3.5. Others
      • 5.3.1.2.4. By End-user
        • 5.3.1.2.4.1. Hospitals
        • 5.3.1.2.4.2. Ambulatory Surgical Centers
        • 5.3.1.2.4.3. Others
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Anesthesia Drugs Market Outlook, 2018-2032F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Turkey
• 6.9. Poland

7. Asia-Pacific Anesthesia Drugs Market Outlook, 2018-2032F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Anesthesia Drugs Market Outlook, 2018-2032F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Anesthesia Drugs Market Outlook, 2018-2032F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Clinical Trial Overview

18. Competitive Landscape

• 18.1. Competition Matrix of Top 5 Market Leaders
• 18.2. SWOT Analysis for Top 5 Players
• 18.3. Key Players Landscape for Top 10 Market Players
  • 18.3.1. Baxter International Inc.
    • 18.3.1.1. Company Details
    • 18.3.1.2. Key Management Personnel
    • 18.3.1.3. Products and Services
    • 18.3.1.4. Financials (As Reported)
    • 18.3.1.5. Key Market Focus and Geographical Presence
    • 18.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 18.3.2. AstraZeneca plc
  • 18.3.3. AbbVie Inc.
  • 18.3.4. B. Braun Melsungen AG
  • 18.3.5. Fresenius SE & Co. KgaA
  • 18.3.6. Hospira Inc.
  • 18.3.7. Pfizer Inc.
  • 18.3.8. Aspen Pharmacare Holdings Limited
  • 18.3.9. Hikama Pharmaceuticals plc
  • 18.3.10. Novartis AG

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

19. Strategic Recommendations

20. About Us and Disclaimer